MAPK1 and neoplasm: P38 contributes to chemotherapeutic resistance in several tumor types, e.g., in response to doxorubicin, cis-platinum, or other agents that target DNA damage, as p38 will promote cell survival of p53-deficient cancer cells through MK2-mediated cell cycle arrest [128,129].